{
    "clinical_study": {
        "@rank": "53770", 
        "acronym": "TAVI", 
        "arm_group": [
            {
                "arm_group_label": "unprotected TAVI", 
                "arm_group_type": "No Intervention", 
                "description": "standard unprotected Transcatheter Aortic Valve Implantation"
            }, 
            {
                "arm_group_label": "TAVI with the TriGuard HDH", 
                "arm_group_type": "Experimental", 
                "description": "TAVI with the TriGuard HDH embolic deflection device"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized evaluation of the TriGuard\u2122 HDH embolic deflection device during transcatheter\n      aortic valve implantation."
        }, 
        "brief_title": "DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard\u2122 HDH Embolic Deflection Device During TAVI", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Valve Stenosis", 
        "condition_browse": {
            "mesh_term": "Aortic Valve Stenosis"
        }, 
        "detailed_description": {
            "textblock": "The TriGuard HDH device is an aortic embolism deflection device intended to reduce the\n      amount of embolic material that may enter the carotid, subclavian, and vertebral arteries\n      during transcatheter heart valve implantation.\n\n      To assess the safety, efficacy, and performance of the TriGuard HDH embolic deflection\n      device in patients undergoing transcatheter aortic valve implantation (TAVI), in comparison\n      with patients undergoing unprotected TAVI.\n\n      Subjects with indications for TAVI and who meet study eligibility criteria will be\n      randomized 1:1 to one of two treatment arms:\n\n        -  Intervention - TAVI with the TriGuard HDH embolic deflection device\n\n        -  Control - standard unprotected TAVI"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient is a male or non-pregnant female \u226518 years of age\n\n          -  Patient meets indications for TAVI\n\n          -  The patient is willing to comply with protocol-specified follow-up evaluations\n\n          -  The patient, or legally authorized representative, has been informed of the nature of\n             the study, agrees to its provisions and has provided written informed consent,\n             approved by the appropriate Medical Ethics Committee (EC) or Institutional Review\n             Board (IRB)\n\n        Exclusion Criteria:\n\n          -  Patients undergoing TAVI via the trans-axillary, trans-subclavian, or trans-aortic\n             route\n\n          -  Patients undergoing TAVI via the transapical approach due to friable or mobile\n             atherosclerotic plaque in the aortic arch\n\n          -  Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year\n             following index procedure. Female subjects of child-bearing potential must have a\n             negative pregnancy test done within 7 days prior to index procedure per site standard\n             test\n\n          -  Patients with  known diagnosis of acute myocardial infarction (AMI) within 72 hours\n             preceding the index procedure (according to definition) or AMI >72 hours preceding\n             the index procedure, in whom creatine kinase and creatine kinase-Muscle Brain have\n             not returned to within normal limits at the time of procedure.\n\n          -  Patients who are currently experiencing clinical symptoms consistent with new-onset\n             AMI, such as nitrate-unresponsive prolonged chest pain\n\n          -  Patients with a history of bleeding diathesis or coagulopathy or patients in whom\n             anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse\n             transfusion\n\n          -  Patients with known other mental or physical illness or known history of substance\n             abuse that may cause non-compliance with the protocol, confound the data\n             interpretation, or is associated with a life expectancy of less than one year\n\n          -  Patients with severe allergy to heparin or known hypersensitivity or contraindication\n             to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, and/or\n             contrast sensitivity that cannot be adequately pre-medicated\n\n          -  Patients with a history of a stroke or transient ischemic attack (TIA) within the\n             prior 6 months\n\n          -  Patients with an active peptic ulcer or history of upper gastrointestinal (GI)\n             bleeding within the prior 6 months\n\n          -  Patients with renal failure (estimated Glomerular Filtration Rate [estimated\n             Glomerular Filtration Rate] <30 mL/min, calculated from serum creatinine by the\n             Cockcroft-Gault formula)\n\n          -  Patients with hepatic failure (Child-Pugh class C)\n\n          -  Patients with hypercoagulable states that cannot be corrected by additional\n             periprocedural heparin\n\n          -  Patients presenting with cardiogenic shock or severe hypotension (systolic blood\n             pressure <90 mm Hg) at the time of the index procedure\n\n          -  Patients with severe peripheral arterial disease that precludes delivery sheath\n             vascular access\n\n          -  Patients with a heavily calcified or severely atheromatous aortic arch\n\n          -  Patients with an innominate artery ostium diameter <11 mm\n\n          -  Patients with a transverse aortic diameter >40 mm\n\n          -  Patients with anatomic irregularities of the aortic arch or innominate artery that\n             could prevent positioning and stability of the device\n\n          -  Patients with contraindication to cerebral MRI\n\n          -  Patients who have a planned treatment with any other investigational device or\n             procedure during the study period\n\n          -  Patients planned to undergo any other cardiac surgical or interventional procedure\n             (e.g., concurrent coronary revascularization) during the TAVI procedure or within two\n             (2) weeks prior to the TAVI procedure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02070731", 
            "org_study_id": "DEFLECT III"
        }, 
        "intervention": {
            "arm_group_label": "TAVI with the TriGuard HDH", 
            "description": "TAVI with the TriGuard HDH embolic deflection device", 
            "intervention_name": "TriGuard HDH", 
            "intervention_type": "Device", 
            "other_name": "TriGuard HDH embolic deflection device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "TAVR", 
        "lastchanged_date": "March 3, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Martin Gilard, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital de la Cavale Blanche"
                }, 
                "investigator": {
                    "last_name": "Martin Gilard, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Thomas Cuisset, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "Clinique chez APHM"
                }, 
                "investigator": {
                    "last_name": "Thomas Cuisset, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stefan Spitzer, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany"
                    }, 
                    "name": "Praxisklinik Herz Und Gef\u00e4sse"
                }, 
                "investigator": {
                    "last_name": "Stefan Spitzer, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jochen Rein\u00f6hl, Md"
                }, 
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany"
                    }, 
                    "name": "Universit\u00e4ts-Herzzentrum Freiburg"
                }, 
                "investigator": {
                    "last_name": "Jochen Rein\u00f6hl, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Joachim Schofer, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }, 
                    "name": "Medical care center"
                }, 
                "investigator": {
                    "last_name": "Joachim Schofer, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Haude, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Neuss", 
                        "country": "Germany"
                    }, 
                    "name": "St\u00e4dtische Kliniken Neuss"
                }, 
                "investigator": {
                    "last_name": "Michael Haude, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gil Bolotin, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel"
                    }, 
                    "name": "Rambam Medical Center"
                }, 
                "investigator": {
                    "last_name": "Gil Bolotin, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Giora Weitz, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel"
                    }, 
                    "name": "Shaarey Tzedek"
                }, 
                "investigator": {
                    "last_name": "Giora Weitz, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Corrado Tamburino, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Catania", 
                        "country": "Italy"
                    }, 
                    "name": "Ferrarotto hospital"
                }, 
                "investigator": {
                    "last_name": "Corrado Tamburino, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Pieter Stella, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands"
                    }, 
                    "name": "UMC Utrecht"
                }, 
                "investigator": {
                    "last_name": "Pieter Stella, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David Heldick Smith, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Brighton", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Royal Sussex County Hospital"
                }, 
                "investigator": {
                    "last_name": "David Heldick Smith, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andreas Baumbach, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Bristol Heart Institute"
                }, 
                "investigator": {
                    "last_name": "Andreas Baumbach, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Daniel Blackman, Md."
                }, 
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Leeds General Infirmary"
                }, 
                "investigator": {
                    "last_name": "Daniel Blackman, Md.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Israel", 
                "Italy", 
                "Netherlands", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized Evaluation of the TriGuard\u2122 HDH Embolic Deflection Device During Transcatheter Aortic Valve Implantation", 
        "overall_contact": {
            "email": "andreas.baumbach@UHBristol.nhs.uk", 
            "last_name": "Andreas Baumbach, Md.", 
            "phone": "44 (0) 117 342 6573"
        }, 
        "overall_official": {
            "affiliation": "Bristol Heart Institute", 
            "last_name": "Andreas Baumbach, Md.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In-hospital procedural safety, defined as the composite of the following Major Adverse Cardiovascular and Cerebrovascular Events (MACCE):\nAll-cause mortality\nAll stroke (disabling and non-disabling)\nLife threatening (or disabling) bleeding\nAcute kidney injury - Stage 2 or 3 (including renal replacement therapy)\nMajor vascular complications", 
            "measure": "In hospital procedural safety", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 7 days during post procedure hospitalization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02070731"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Keystone Heart", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Keystone Heart", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}